ICON Public’s (ICLR) Buy Rating Reiterated at Truist Financial

ICON Public (NASDAQ:ICLR)‘s stock had its “buy” rating restated by research analysts at Truist Financial in a report released on Wednesday,Benzinga reports. They presently have a $284.00 target price on the medical research company’s stock, down from their previous target price of $295.00. Truist Financial’s target price indicates a potential upside of 39.48% from the company’s previous close.

A number of other research analysts also recently issued reports on the company. Evercore ISI reduced their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Redburn Atlantic initiated coverage on shares of ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 price target for the company. The Goldman Sachs Group decreased their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Baird R W lowered ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, Barclays cut their target price on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $289.10.

ICON Public Stock Up 0.2 %

NASDAQ:ICLR traded up $0.35 during trading hours on Wednesday, reaching $203.61. The company had a trading volume of 39,883 shares, compared to its average volume of 754,279. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The firm has a market cap of $16.80 billion, a price-to-earnings ratio of 22.70, a P/E/G ratio of 1.57 and a beta of 1.21. The business’s 50-day simple moving average is $230.58 and its two-hundred day simple moving average is $284.89.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the business earned $3.10 earnings per share. ICON Public’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities analysts expect that ICON Public will post 13.42 earnings per share for the current year.

Institutional Trading of ICON Public

Institutional investors have recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC bought a new stake in shares of ICON Public in the 2nd quarter valued at about $54,000. EverSource Wealth Advisors LLC increased its stake in shares of ICON Public by 39.2% in the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after buying an additional 111 shares during the period. Whittier Trust Co. of Nevada Inc. raised its holdings in ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after buying an additional 226 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares during the last quarter. Finally, Crestwood Advisors Group LLC bought a new position in shares of ICON Public during the second quarter valued at about $288,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.